Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Size

• The Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) market size was valued at USD 22.64 million in 2025 and is expected to reach USD 33.19 million by 2033, at a CAGR of 4.9% during the forecast period
• The market growth is largely driven by increasing investments in regenerative medicine research, expanding stem cell therapy applications, and rising collaborations between research institutes, biotechnology companies, and healthcare organizations across the region
• Furthermore, growing demand for advanced disease modeling, drug discovery, personalized medicine, and cell-based therapies is positioning induced pluripotent stem cells (iPSCs) as a critical component of next-generation biomedical research and therapeutic development. These converging factors are accelerating the adoption of iPSC technologies, thereby significantly boosting the market’s growth

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Analysis

• Induced pluripotent stem cells (iPSCs), which are genetically reprogrammed adult cells capable of developing into multiple cell types, are becoming increasingly important in regenerative medicine, disease modeling, and drug discovery applications across the Middle East and Africa due to their significant potential in personalized medicine and advanced therapeutic research
• The rising demand for induced pluripotent stem cells (iPSCs) is primarily driven by increasing investments in stem cell research, growing prevalence of chronic and rare diseases, and expanding collaborations among biotechnology companies, academic institutions, and healthcare organizations focused on regenerative medicine innovation
• Saudi Arabia dominated the Middle East and Africa induced pluripotent stem cells (iPSCs) market with the largest revenue share of 34.8% in 2025, supported by improving healthcare infrastructure, increasing government support for biotechnology research, and growing investments in precision medicine initiatives, with research institutions and biotechnology firms actively advancing stem cell-based therapeutic development
• South Africa is expected to be the fastest growing country in the Middle East and Africa induced pluripotent stem cells (iPSCs) market during the forecast period due to expanding biomedical research activities, increasing healthcare investments, and rising awareness regarding advanced cell-based therapies
• Drug discovery and development segment dominated the Middle East and Africa induced pluripotent stem cells (iPSCs) market with a market share of 41.6% in 2025, driven by the increasing adoption of iPSC-based models for toxicity testing, disease modeling, and personalized drug screening applications across pharmaceutical and biotechnology research programs

Report Scope and Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Segmentation

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Trends

“Rising Integration of iPSC Technology in Regenerative Medicine and Precision Therapeutics”

• A significant and accelerating trend in the Middle East and Africa induced pluripotent stem cells (iPSCs) market is the increasing integration of iPSC technologies in regenerative medicine, disease modeling, and precision therapeutics research across biotechnology companies and academic institutions. This integration is significantly enhancing the development of advanced cell-based therapies and personalized treatment solutions
• For instance, research institutes and biotechnology organizations in Saudi Arabia and the UAE are increasingly utilizing iPSC platforms for neurological disorder studies, tissue regeneration research, and personalized drug screening applications. Similarly, South African research centers are exploring iPSC-based technologies for chronic disease modeling and translational medicine programs
• The integration of iPSC technology enables researchers to generate patient-specific cell lines for studying disease mechanisms, evaluating drug toxicity, and identifying targeted therapies with greater precision. For instance, several biotechnology firms are utilizing iPSC-derived models to improve therapeutic discovery processes and accelerate regenerative medicine innovation. Furthermore, the growing use of automated cell reprogramming and advanced bioinformatics tools is improving the efficiency and scalability of iPSC research activities
• The seamless integration of induced pluripotent stem cells (iPSCs) with genomic technologies, artificial intelligence-driven analytics, and biobanking platforms is facilitating more comprehensive biomedical research capabilities. Through integrated research frameworks, organizations can accelerate stem cell characterization, therapeutic validation, and precision medicine development, creating a more advanced and interconnected healthcare research environment
• This trend towards more advanced, scalable, and patient-specific stem cell research solutions is fundamentally reshaping expectations for regenerative medicine development. Consequently, companies and research institutes across the Middle East and Africa are investing in iPSC-based platforms with enhanced capabilities for disease modeling, cell therapy development, and personalized medicine applications
• The demand for induced pluripotent stem cells (iPSCs) offering high-efficiency reprogramming, scalable production capabilities, and improved therapeutic potential is growing rapidly across research and clinical sectors, as healthcare organizations increasingly prioritize advanced regenerative medicine and precision healthcare solutions

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Dynamics

Driver

“Growing Demand Due to Expanding Regenerative Medicine Research and Rising Chronic Disease Burden”

• The increasing focus on regenerative medicine research across healthcare and biotechnology sectors, coupled with the rising prevalence of chronic and genetic disorders, is a significant driver for the heightened demand for induced pluripotent stem cells (iPSCs)
• For instance, in March 2025, research organizations and biotechnology companies across Saudi Arabia and the UAE expanded investments in stem cell research initiatives focused on neurological disorders, cardiovascular diseases, and precision medicine development. Such strategies by key organizations are expected to drive the induced pluripotent stem cells (iPSCs) market growth during the forecast period
• As healthcare providers and researchers seek more effective approaches for disease modeling and therapeutic development, induced pluripotent stem cells (iPSCs) offer advanced capabilities such as patient-specific cell generation, toxicity testing, and regenerative tissue development, providing a compelling alternative to conventional research models
• Furthermore, the growing adoption of personalized medicine approaches and increasing investments in biotechnology innovation are making induced pluripotent stem cells (iPSCs) an integral component of next-generation therapeutic research, offering seamless integration with genomic analysis, drug discovery platforms, and translational medicine applications
• The ability to develop patient-derived cellular models, accelerate drug screening processes, and support regenerative therapy research are key factors propelling the adoption of induced pluripotent stem cells (iPSCs) across academic, pharmaceutical, and biotechnology sectors. The growing establishment of stem cell research centers and increasing government support for biotechnology infrastructure further contribute to market growth

Restraint/Challenge

“High Research Costs and Ethical Regulatory Challenges”

• Concerns surrounding the high costs associated with induced pluripotent stem cells (iPSCs) research, along with complex regulatory and ethical frameworks, pose a significant challenge to broader market expansion. As iPSC development requires specialized laboratory infrastructure, advanced technologies, and skilled professionals, research activities often involve substantial operational and compliance expenditures
• For instance, varying regulatory policies related to stem cell research and clinical applications across Middle East and African countries have created challenges for biotechnology companies and research institutions seeking large-scale commercialization and therapeutic approvals
• Addressing these regulatory and operational challenges through standardized research guidelines, improved funding support, and enhanced collaboration frameworks is crucial for accelerating market development. Companies and research organizations are increasingly emphasizing quality assurance standards, ethical compliance measures, and advanced manufacturing practices to strengthen research reliability and therapeutic potential. In addition, the relatively high cost of iPSC generation, maintenance, and storage compared to conventional cell culture technologies can be a barrier to adoption for smaller research institutes and emerging biotechnology firms, particularly in developing economies
• While investments in biotechnology infrastructure are gradually increasing, the significant financial and technical requirements associated with induced pluripotent stem cells (iPSCs) research can still limit widespread adoption, especially for organizations with restricted research budgets or limited access to advanced laboratory resources
• Overcoming these challenges through stronger regulatory harmonization, increased government and private sector investments, and the development of more cost-effective stem cell technologies will be vital for sustained market growth

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Scope

The market is segmented on the basis of cell source, type, product, applications, end user, and distribution channel.

• By Cell Source

On the basis of cell source, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. The skin cells segment dominated the market with the largest market revenue share in 2025, driven by the widespread use of skin fibroblasts in cellular reprogramming and regenerative medicine research. Skin cells are commonly utilized due to their easy accessibility, high reprogramming efficiency, and suitability for generating patient-specific iPSC lines. Research institutions and biotechnology companies increasingly prefer skin-derived iPSCs for disease modeling, toxicity testing, and personalized medicine applications. The growing number of stem cell research initiatives and expanding adoption of regenerative therapies further contribute to the dominance of this segment. In addition, advancements in cell culturing and reprogramming technologies are enhancing the efficiency and scalability of skin cell-derived iPSC production across the region.

The blood cells segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing demand for minimally invasive cell collection procedures and advancements in hematological research applications. Blood-derived iPSCs are gaining popularity due to their convenience in sample collection and reduced patient discomfort compared to traditional biopsy-based methods. The growing focus on personalized medicine and immune-related disease studies is accelerating the utilization of blood cell-based reprogramming technologies. Furthermore, improvements in cell isolation techniques and genomic analysis capabilities are supporting the adoption of blood-derived iPSCs in translational medicine research. Expanding collaborations between biotechnology firms and academic institutions are also expected to drive innovation and commercialization within this segment.

• By Type

On the basis of type, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into human IPSCs and mouse IPSCs. The human IPSCs segment held the largest market revenue share in 2025 driven by the increasing demand for patient-specific disease models and regenerative medicine research. Human iPSCs provide greater clinical relevance for drug discovery, toxicity testing, and therapeutic development compared to conventional animal models. Research organizations and pharmaceutical companies are extensively utilizing human iPSCs for studying neurological disorders, cardiovascular diseases, and rare genetic conditions. The segment is also benefiting from rising investments in precision medicine and stem cell-based therapy development initiatives across the region. In addition, technological advancements in genome editing and cell differentiation methods are further strengthening the adoption of human IPSCs in biomedical research applications.

The mouse IPSCs segment is expected to witness the fastest CAGR from 2026 to 2033, driven by increasing utilization in preclinical research and experimental biology studies. Mouse IPSCs are widely used for understanding developmental biology, gene function analysis, and translational medicine research due to their cost-effectiveness and established laboratory protocols. Researchers continue to rely on mouse-based stem cell models for early-stage therapeutic validation and regenerative medicine experimentation. Furthermore, growing academic collaborations and government-supported biomedical research programs are contributing to the expansion of this segment. Advancements in genetic engineering and transgenic animal model development are also expected to accelerate the use of mouse IPSCs in future research activities.

• By Product

On the basis of product, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into instruments, consumables & kits, and services. The consumables & kits segment dominated the market with the largest market revenue share in 2025, driven by the recurring demand for reagents, culture media, assay kits, and cell reprogramming materials in stem cell research workflows. Biotechnology companies and research laboratories require a continuous supply of specialized consumables for cell maintenance, differentiation, and genomic analysis activities. The increasing volume of regenerative medicine research and disease modeling studies is further boosting the demand for high-quality consumables and laboratory kits. In addition, advancements in standardized stem cell protocols and automated cell culture systems are enhancing the efficiency of consumable utilization across research settings. The growing establishment of stem cell research centers in the Middle East and Africa also supports the dominance of this segment.

The services segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing outsourcing of stem cell characterization, genomic testing, and cell banking services by research institutions and pharmaceutical companies. Organizations are increasingly relying on specialized service providers to reduce operational complexities and improve research efficiency. The rising adoption of contract research services and customized iPSC generation solutions is supporting market growth within this segment. Furthermore, expanding collaborations between biotechnology firms and academic organizations are accelerating the commercialization of stem cell-based services across the region. Improvements in laboratory automation and data analytics capabilities are also expected to enhance the accessibility and scalability of iPSC-related service offerings.

• By Applications

On the basis of applications, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into academic research, regenerative medicine, cellular therapy, toxicology screening, drug discovery and development, disease modelling, stem cell banking, 3D bio printing, and others. The drug discovery and development segment dominated the market with the largest market revenue share of 41.6% in 2025, driven by the increasing use of iPSC-derived cellular models for toxicity testing, therapeutic screening, and precision medicine research. Pharmaceutical and biotechnology companies are utilizing iPSC technologies to improve drug development efficiency and reduce dependency on conventional animal testing methods. The growing prevalence of chronic and rare diseases is also accelerating the need for advanced disease-specific cellular models. Furthermore, increasing investments in regenerative medicine innovation and translational research programs are strengthening the adoption of iPSC-based drug discovery platforms. Technological advancements in high-throughput screening and genomic profiling are further supporting the growth of this segment across the region.

The regenerative medicine segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing interest in stem cell-based therapies for neurological, cardiovascular, and orthopedic disorders. Healthcare organizations and biotechnology firms are expanding research initiatives focused on tissue engineering and cellular regeneration applications. The growing adoption of personalized medicine approaches and advancements in stem cell differentiation technologies are also contributing to the expansion of this segment. Furthermore, rising government support for biotechnology innovation and clinical research activities is encouraging the development of regenerative medicine programs across the Middle East and Africa. Increasing collaborations between research institutes and healthcare providers are expected to further accelerate the commercialization of regenerative stem cell therapies.

• By End User

On the basis of end user, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into biotechnology & pharmaceutical companies, research laboratories, diagnostic laboratories, and others. The research laboratories segment dominated the market with the largest market revenue share in 2025, driven by the growing number of stem cell research projects and academic collaborations focused on regenerative medicine and disease modeling studies. Research laboratories are increasingly utilizing iPSC technologies for cellular analysis, genomic studies, and therapeutic discovery applications. The expansion of government-funded biomedical research initiatives and rising investments in advanced laboratory infrastructure are further contributing to segment growth. In addition, increasing partnerships between universities and biotechnology firms are supporting the adoption of innovative stem cell technologies across research environments. Advancements in laboratory automation and bioinformatics platforms are also improving research efficiency and scalability within this segment.

The biotechnology & pharmaceutical companies segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing investments in personalized medicine, cell therapy development, and drug screening programs. Biotechnology and pharmaceutical firms are rapidly adopting iPSC technologies to accelerate therapeutic discovery and optimize preclinical testing processes. The growing demand for patient-specific cellular models and precision therapeutics is also supporting the expansion of this segment. Furthermore, strategic collaborations between pharmaceutical companies and stem cell technology providers are enhancing innovation and commercialization opportunities. The increasing focus on reducing drug development timelines and improving treatment outcomes is expected to further drive segment growth during the forecast period.

• By Distribution Channel

On the basis of distribution channel, the Middle East and Africa induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. The direct tender segment dominated the market with the largest market revenue share in 2025, driven by the strong preference of research institutes, hospitals, and biotechnology organizations for direct procurement agreements with manufacturers and suppliers. Direct tender channels provide bulk purchasing advantages, customized product solutions, and long-term supply reliability for stem cell research activities. The growing number of government-funded biomedical research programs and institutional procurement contracts is further supporting the dominance of this segment. In addition, direct collaboration between suppliers and research organizations helps ensure regulatory compliance and product quality assurance. Increasing investments in advanced laboratory infrastructure across the Middle East and Africa are also contributing to segment expansion.

The retail sales segment is expected to witness the fastest CAGR from 2026 to 2033, driven by the increasing availability of stem cell research consumables, laboratory kits, and specialized reagents through commercial distribution networks. Small research laboratories and emerging biotechnology firms are increasingly relying on retail sales channels for convenient product access and flexible purchasing options. The expansion of e-commerce platforms and scientific supply distributors is also improving market accessibility across developing economies. Furthermore, rising awareness regarding stem cell technologies and growing participation of private research organizations are contributing to the growth of this segment. Advancements in digital procurement systems and inventory management solutions are expected to further strengthen retail sales channels in the coming years

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Regional Analysis

• Saudi Arabia dominated the Middle East and Africa induced pluripotent stem cells (iPSCs) market with the largest revenue share of 34.8% in 2025, supported by improving healthcare infrastructure, increasing government support for biotechnology research, and growing investments in precision medicine initiatives
• Research institutions and biotechnology organizations in the country highly value the disease modeling capabilities, therapeutic development potential, and personalized medicine applications offered by induced pluripotent stem cells (iPSCs) for advanced biomedical research and drug discovery activities
• This growing adoption is further supported by improving healthcare infrastructure, increasing collaborations between academic institutions and biotechnology companies, and the rising focus on precision medicine and stem cell-based therapies, establishing induced pluripotent stem cells (iPSCs) as a critical component of next-generation regenerative medicine research across the country

The Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Market Insight

The Saudi Arabia induced pluripotent stem cells (iPSCs) market captured the largest revenue share in 2025 within the Middle East and Africa, fueled by increasing investments in regenerative medicine research and the expanding biotechnology sector. Research institutions and healthcare organizations are increasingly prioritizing the development of advanced stem cell therapies and personalized medicine solutions. The growing focus on precision healthcare, combined with strong government initiatives supporting biotechnology innovation and biomedical infrastructure development, further propels the induced pluripotent stem cells (iPSCs) industry. Moreover, the increasing collaboration between academic institutions, biotechnology companies, and healthcare providers is significantly contributing to the market's expansion.

UAE Induced Pluripotent Stem Cells (iPSCs) Market Insight

The UAE induced pluripotent stem cells (iPSCs) market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the increasing focus on healthcare innovation and the growing demand for advanced regenerative medicine technologies. In addition, rising investments in biomedical research and precision medicine initiatives are encouraging research organizations and biotechnology companies to adopt stem cell-based solutions. The UAE’s expanding biotechnology ecosystem, alongside its strong healthcare infrastructure and supportive government initiatives, is expected to continue to stimulate market growth.

South Africa Induced Pluripotent Stem Cells (iPSCs) Market Insight

The South Africa induced pluripotent stem cells (iPSCs) market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness regarding stem cell research and the demand for advanced therapeutic development technologies. South Africa’s improving healthcare and research infrastructure, combined with its emphasis on biotechnology innovation and translational medicine, promotes the adoption of induced pluripotent stem cells (iPSCs), particularly in academic and pharmaceutical research environments. The integration of stem cell technologies with genomic analysis and disease modeling platforms is also becoming increasingly prevalent, with a strong preference for advanced and scalable biomedical research solutions aligning with evolving healthcare objectives.

Egypt Induced Pluripotent Stem Cells (iPSCs) Market Insight

The Egypt induced pluripotent stem cells (iPSCs) market is gaining momentum due to the country’s growing biotechnology sector, expanding healthcare infrastructure, and increasing investment in biomedical research. The Egyptian market places a significant emphasis on regenerative medicine and disease research, and the adoption of induced pluripotent stem cells (iPSCs) is driven by the increasing number of academic and pharmaceutical research initiatives. The integration of stem cell technologies with genomic research and drug development platforms is fueling growth. Moreover, Egypt’s focus on strengthening healthcare innovation and expanding precision medicine capabilities is likely to spur demand for advanced stem cell research solutions across research and clinical sectors.

Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market Share

The Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) industry is primarily led by well-established companies, including:

• FUJIFILM Cellular Dynamics, Inc. (U.S.)
• STEMCELL Technologies (Canada)
• Lonza Group AG (Switzerland)
• Century Therapeutics, Inc. (U.S.)
• BlueRock Therapeutics LP (U.S.)
• Fate Therapeutics, Inc. (U.S.)
• REPROCELL Inc. (Japan)
• Pluri Inc. (Israel)
• Ncardia USA LLC (U.S.)
• Applied StemCell, Inc. (U.S.)
• Axol Bioscience Ltd (U.K.)
• Bit Bio Ltd (U.K.)
• Evotec SE (Germany)
• Sana Biotechnology, Inc. (U.S.)
• Novo Nordisk A/S (Denmark)
• Takara Bio Inc. (Japan)
• Thermo Fisher Scientific Inc. (U.S.)
• Danaher (U.S.)
• Corning Incorporated (U.S.)
• Bio-Techne Corporation (U.S.)

What are the Recent Developments in Middle East and Africa Induced Pluripotent Stem Cells (iPSCs) Market?

• In January 2025, the Abu Dhabi Stem Cells Center announced the successful development of virus-free, clinical-grade induced pluripotent stem cells (iPSCs) compliant with Good Manufacturing Practice (GMP) standards for the first time in the Middle East. The development utilized proprietary in-house protocols designed to improve safety and precision in regenerative medicine applications, including therapies for neurological disorders and diabetes. This milestone strengthened the UAE’s position as a regional hub for advanced stem cell and precision medicine research
• In January 2025, the Abu Dhabi Stem Cells Center entered into a collaboration with Kyoto University and Japanese biotechnology company Rege Nephro to advance diabetes treatment research using induced pluripotent stem cells (iPSCs) derived from pancreatic beta cells. The partnership focuses on developing innovative regenerative medicine therapies and expanding translational research capabilities within the Middle East region
• In December 2023, researchers from King Faisal Specialist Hospital & Research Centre and collaborating institutions published a study on HLA-based banking of induced pluripotent stem cells (iPSCs) in Saudi Arabia. The initiative aimed to establish a genetically representative iPSC biobank to support regenerative medicine and cell therapy applications tailored to the Saudi population. The study marked a significant advancement in stem cell infrastructure and precision medicine development within the Middle East
• In October 2023, researchers from Middle East Technical University developed and characterized a human induced pluripotent stem cell line carrying a mutation linked to primary familial brain calcification (PFBC). The research supports advanced neurological disease modeling and enables more accurate studies for rare genetic disorders using patient-derived stem cell technologies. This development highlighted the growing research capabilities for iPSC-based disease modeling within the broader Middle East region
• In August 2023, researchers from Ankara University Biotechnology Institute reported advancements in differentiating endothelial progenitor and vascular smooth muscle cells from induced pluripotent stem cells (iPSCs). The study focused on improving cardiovascular regenerative medicine research and vascular tissue engineering applications using stem cell-derived cellular models. The development contributed to expanding translational medicine and regenerative therapy research activities across the Middle East region

SKU-66913